Robert Gordon

Author PubWeight™ 30.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 2004 1.67
2 Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 2003 1.35
3 The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 2009 1.32
4 Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007 1.28
5 Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006 1.24
6 An Australian casemix classification for palliative care: lessons and policy implications of a national study. Palliat Med 2004 1.08
7 Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging 2012 1.03
8 The last drag: an evaluation of an LGBT-specific smoking intervention. J Homosex 2012 0.99
9 Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem 2011 0.97
10 Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005 0.97
11 The development of Version 2 of the AN-SNAP casemix classification system. Aust Health Rev 2007 0.95
12 Transport and deposition of sediment-associated Escherichia coli in natural streams. Water Res 2005 0.94
13 An Australian casemix classification for palliative care: technical development and results. Palliat Med 2004 0.93
14 Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species. Eur J Pharmacol 2007 0.92
15 Clinical specialists and advanced practitioners in physical therapy: a survey of physical therapists and employers of physical therapists in ontario, Canada. Physiother Can 2008 0.91
16 Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol 2007 0.88
17 Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 2013 0.86
18 Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists. Bioorg Med Chem Lett 2011 0.85
19 Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett 2006 0.85
20 Health services research and development in practice: an Australian experience. J Health Serv Res Policy 2003 0.85
21 Complex HeartMate II infection treated with pump exchange to HeartWare HVAD. ASAIO J 2013 0.85
22 Traumatic shoulder injuries: a force mechanism analysis-glenohumeral dislocation and instability. AJR Am J Roentgenol 2013 0.84
23 Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists. Bioorg Med Chem Lett 2005 0.84
24 Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett 2010 0.83
25 Characterization of platelet-derived growth factor-C (PDGF-C): expression in normal and tumor cells, biological activity and chromosomal localization. Int J Biochem Cell Biol 2002 0.83
26 Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 2003 0.81
27 Improving operating theatre communication between the orthopaedics surgeon and radiographer. ANZ J Surg 2013 0.78
28 Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 2003 0.78
29 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. Bioorg Med Chem Lett 2003 0.78
30 Findings From the National Machine Guarding Program: A Small Business Intervention: Lockout/Tagout. J Occup Environ Med 2016 0.77
31 The development of potent non-peptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004 0.76
32 Guidelines for the practice and performance of manipulation under anesthesia. Chiropr Man Therap 2014 0.75
33 Findings From the National Machine Guarding Program-A Small Business Intervention: Machine Safety. J Occup Environ Med 2016 0.75
34 Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. Transplantation 2017 0.75
35 The right to refuse treatment: Commonwealth developments and issues. Int J Law Psychiatry 1983 0.75
36 Sense and Sensibility When Prescribing 'Off-Label' to Psychiatric Patients. Curr Pharm Des 2015 0.75
37 Traumatic shoulder injuries: a force mechanism analysis of complex injuries to the shoulder girdle and proximal humerus. AJR Am J Roentgenol 2013 0.75
38 Findings From the National Machine Guarding Program: Safety Climate, Hazard Assessment, and Safety Leadership in Small Metal Fabrication Businesses. J Occup Environ Med 2017 0.75
39 Hemolysis and pump failure secondary to spontaneous bend relief disconnection in a HeartMate II device with a sealed outlet graft. J Heart Lung Transplant 2012 0.75
40 Bacterial Pathogen Indicator Transport from Livestock Mortality Biopiles. J Environ Qual 2015 0.75
41 Assessment of denitrification gaseous end-products in the soil profile under two water table management practices using repeated measures analysis. J Environ Qual 2005 0.75
42 Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile. Bioorg Med Chem Lett 2002 0.75
43 Modeling E.coli fate and transport in treatment wetlands using the water quality analysis and simulation program. J Environ Sci Health A Tox Hazard Subst Environ Eng 2011 0.75
44 Platelet-Rich Growth Factor for Lip and Perioral Rejuvenation. A Case Study on "The Kiss Shot". Dent Today 2016 0.75